Long-term safety of solriamfetol for ADHD in children and teens
Treatments studied
Part of Mental health clinical trials.
This study checks the long-term safety of the drug solriamfetol for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents who have already completed an earlier study of this medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed either the FOCUS-2 or FOCUS-3 study of solriamfetol for ADHD.
- A parent or legal guardian must be able to give written permission, and you must be willing to agree (assent) to take part.
- You must be able to follow the study's rules and procedures.
- The study doctor must decide that it is safe and appropriate for you to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medication called solriamfetol can safely help children with ADHD. If your child is between 6 and 12 years old and has ADHD, this study may be an option.
This study tests a new medicine, solriamfetol, to see if it helps teenagers with ADHD. The medicine is taken as a tablet and may improve focus and reduce symptoms.
This study looks at how stimulant medications and small movements during an fMRI brain scan affect attention in teens and adults with ADHD. You will be asked to do a computer task while in the scanner, and the results may help improve ADHD treatments.
This study compares stimulant and non-stimulant ADHD medicines in kids who have not taken ADHD medication before. It also studies how these treatments affect brain “reward” processes, which may be linked to substance-use risk.
This study uses brain scans (EEG) to understand which children with ADHD will respond well to stimulant medications. The goal is to help doctors choose the right treatment faster by looking at brain activity patterns before starting medication.
This study tests a medication called Solriamfetol (Sunosi) to see if it helps people with shift work disorder stay awake and alert during their shifts. It is a Phase 3 trial, which means it is being studied in a larger group to confirm how well it works and check for side effects.
Hear when a new ADHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.